Elite Pharmaceuticals Inc (ELTP)

[tangerine]

Updated Elite's partners - My money is betting on them


I am going to bet that all these partners that have put all these products in Elite's hands know what they are doing.

HK Pharma - Elite is doing all the work to develop an NDA for an undisclosed Hong Kong Pharma company. This is a new drug approved overseas to be marketed here in the USA, manufactured by Elite


Actavis - 2 product transfers and one NDA in development, all for Mikah designee as noted below

http://www.actavis.us/en/default.htm


Mikah Pharma - designee of Actavis, VP at Actavis consultant to Epic - Product pending now from recent completion of FDA inspections, one more product transfer pending and development of an NDA!!

"Mikah Pharma has contracted Elite Pharmaceuticals to develop and manufacture our top leading products.

Elite will develop MIK001’s formulation, analytical methodology, and manufacture, test and release the clinical supplies necessary for our clinical trials and NDA approval"

http://mikahpharma.com/



Epic Pharma and CTO of Elite, half of BOD of Elite, can own ~50% of Elite. Making 8 products with Elite - One pending now

http://www.epic-pharma.com/


Hi-tech Pharmacal - HITK - Lodrane line, generic of 100m branded product

http://www.hitechpharm.com/


ECR - Lodrane

http://www.ecrpharma.com/


TAGI Pharma - Elite owned ANDAs, also handles Roxane and Epic products. Review the wholesalers being used!! 2 Products pending now from recent completion of FDA inspections.

http://www.tagipharma.com/products.html


The Pharma-Network - Ascend Labs - Methadone

http://www.ascendlaboratories.com/


Novel Labs - Elite owns 10%

"Novel has an aggressive pipeline forecasting 10 to 12 ANDA approvals and product launches per year. In its first year alone, Novel filed 8 ANDAs with the USFDA. Currently, Novel has identified over 50 drug products which are in various stages of development to be commercialized in the coming years. As a tenacious first-to-file generic comapany, Novel is continuously pursuing first-to-file & first-to-market opportunities and to date has been awarded 5 first-to-files while awaiting 2 more.

Novel currently has over 20 ANDAs with the USFDA. 5 of those applications have been approved and 3 have received tentative approvals. To supplement its considerable in-house R&D capabilities, Novel has acquired 8 additional ANDAs from other firms for manufacturing and marketing."

http://www.novellabs.net/

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79145196

Socius - withdrawn financing deal pending new deal with Socius or other options as noted on CCs

New Partners - Elite has other products in the pipeline including another opioid pending FDA approval but no announced marketing partner. Should we add the co-inventors on these new patents now too?